EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6199-6209

  Seethammagari, Mamatha R ^a   Xie, Xiaoming ^a   Greenberg, Norman M ^b   Spencer, David M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; KALLIKREIN; LUCIFERASE; PROBASIN; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CONTROLLED STUDY; EPITHELIUM; IMAGING; IMMUNOHISTOCHEMISTRY; METASTASIS; MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REPORTER GENE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TESTIS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENES, REPORTER; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SENSITIVITY AND SPECIFICITY;

EID: 33745714254     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3954     Document Type: Article

References (35)

1. Kasper S. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 2005;94:279-97.
2. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004;11:225-54.
3. Kasper S, Smith JA, Jr. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004;172:12-9.
4. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 2003;17:545-80.
5. Wirtzfeld LA, Wu G, Bygrave M, et al. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res 2005;65:6337-45.
6. McElroy WD, DeLuca MA. Firefly and bacterial luminescence: basic science and applications. J Appl Biochem 1983;5:197-209.
7. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol 1995;18:593-603.
8. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002;4:235-60.
9. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-8.
10. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002;38:2128-36.
11. Xie X Luo Z, Slawin KM, Spencer DM. The EZC-prostate model: noninvasive prostate imaging in living mice. Mol Endocrinol 2004;18:722-32.
12. Xie X, Zhao X, Liu Y, et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 (hK2) promoter. Hum Gene Ther 2001;12:549-61.
13. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high level of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141:4698-710.
14. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000;60:334-41.
15. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
16. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
17. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
18. Uchida K, Masumori N, Takahashi A, Itoh N, Tsukamoto T. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model. Prostate 2005;62:40-8.
19. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
20. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
21. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671-8a
22. Freeman KW, Welm BE, Gangula RD, et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 2003;63:8256-63.
23. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
24. Zhu P, Baek SH, Bourk EM, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615-29.
25. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92:287-95.
26. Linnoila RI, Zhao B, DeMayo JL, et al. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 2000;60:4005-9.
27. Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001;61:6795-804.
28. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing biological processes in a new light. Genes Dev 2003;17:545-80.
29. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A 2001;98:14595-600.
30. Iyer M, Salazar FB, Lewis X et al. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res 2005;14:47-55.
31. Adams JY, Johnson M, Sato M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002;8:891-7.
32. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003;20:745-56.
33. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101:640-8.
34. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004;92:265-71.
35. Ye X, Han SJ, Tsai SY, et al. Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci U S A 2005;102:9487-92.